Why This Study Matters
Small-cell lung cancer (SCLC) accounts for roughly 15% of all lung cancers, with more than 200,000 cases diagnosed worldwide each year. Nearly all patients relapse after first-line platinum-based chemotherapy, and topotecan has remained the only routinely used second-line option for decades, with modest efficacy historically reported at around a 24% response rate and a median overall survival near 25 weeks versus supportive care — a cross-study historical benchmark rather than a result from this trial. That persistent unmet need has driven interest in B7-H3-targeted antibody-drug conjugates such as tambotatug pelitecan, and the TAISHAN-302 interim results reported here are among the first phase 3 confirmations that this drug class can outperform topotecan.
Study Design
TAISHAN-302 is a multicenter, open-label, randomized, parallel-assignment phase 3 trial. Patients received tambotatug pelitecan monotherapy intravenously once every three weeks, or topotecan hydrochloride intravenously on days 1–5 of each three-week cycle. Because the trial is open-label, both investigators and patients knew the treatment assignment throughout, which carries more risk of assessment bias for investigator-assessed endpoints such as progression-free survival and objective response than for overall survival.
Patient Population
Eligible patients were 18 to 75 years old with an ECOG performance status of 0 or 1 and histologically or cytologically confirmed SCLC (limited- or extensive-stage) that had progressed on or after first-line platinum-based therapy of at least two cycles. Patients with combined or transformed SCLC were excluded, and tumor tissue was required to confirm B7-H3 expression before enrollment; prior treatment with a B7-H3-targeted therapy or a topoisomerase 1 inhibitor/antibody-drug conjugate was also an exclusion.
Primary Endpoint Results
A hazard ratio of 0.46 for death corresponds to a 54% relative reduction in risk, and a hazard ratio of 0.29 for progression or death to a 71% relative reduction; external press coverage of this trial has reported the results in those terms. The published abstract itself states P<0.001 for both endpoints, a less precise threshold than the P<0.0001 some external coverage cites, but consistent with it.
Subgroup Findings
| Subgroup | Tam-Peli | Topotecan | Effect Size |
|---|---|---|---|
| Brain metastases – intracranial PFS | 6.1 months | 4.2 months | HR 0.43 (95% CI, 0.27–0.68) |
| Brain metastases – intracranial response rate | 32.4% | 2.9% | Not reported |
The published abstract does not report subgroup-level statistics. The brain-metastases figures above come only from sponsor press-release and independent media reporting, not from the primary journal publication, and should not be treated as abstract-verified data.
Safety Profile
Per the published abstract, adverse events of grade 3 or higher from any cause were less frequent with tambotatug pelitecan than with topotecan. External reporting adds more granular detail not present in the abstract, using a related but distinct metric — treatment-related adverse events specifically — which is not directly comparable to the any-cause figures the abstract reports.
| Safety Measure | Tam-Peli | Topotecan | Source |
|---|---|---|---|
| Grade ≥3 adverse events (any cause) | 55.4% | 77.9% | Abstract |
| Grade ≥3 treatment-related adverse events | 46.4% | 74.7% | External reporting |
| Serious treatment-related adverse events | 25.9% | 36.4% | External reporting |
| ILD/pneumonitis, all grades | 4.9% | 1.4% | External reporting |
| ILD/pneumonitis, grade 3 | 0.9% | 0.9% | External reporting |
No grade 4 or grade 5 ILD/pneumonitis events were reported in either arm, per external source reporting. These more granular safety figures were not specified in this source's published abstract, so they are reported here as externally sourced rather than abstract-verified.
Interpretation and Broader Context
These interim results suggest tambotatug pelitecan could displace topotecan as the second-line standard of care for relapsed SCLC, an area that has seen little therapeutic advancement in decades. The magnitude of benefit — a stratified hazard ratio of 0.46 for death and 0.29 for progression or death — is substantial for this historically difficult-to-treat population, and the adverse-event profile appears more favorable than topotecan's on the metrics reported.
The second positive phase III trial for Tam-Peli, TAISHAN-302, reinforces our confidence in its potential to improve outcomes for people with cancer.
— Levi Garraway, MD, PhD, Roche Chief Medical Officer and Head of Global Product Development, in a company press release
Tambotatug pelitecan is an antibody-drug conjugate that links a B7-H3-targeted monoclonal antibody to a topoisomerase 1 inhibitor payload via a tumor-microenvironment-activatable linker platform, according to sponsor reporting. B7-H3 is broadly expressed across solid tumors, making this mechanism potentially relevant beyond SCLC, though that broader relevance has not itself been tested here.
Limitations
These results come from a prespecified interim analysis of TAISHAN-302, not a final readout: median overall survival for tambotatug pelitecan was not reached at the upper bound of its confidence interval, so overall survival data remain immature and longer follow-up is needed to confirm how durable the benefit is. The trial is open-label rather than blinded, which carries more risk of assessment bias for investigator-assessed endpoints than for overall survival. The published abstract does not report subgroup-level statistics or per-arm treatment-related adverse-event rates, so the brain-metastases and granular safety figures above are external reporting rather than abstract-verified data, and readers should weigh them accordingly. Enrollment was limited to sites in China, per external reporting the abstract itself does not address, which leaves open how the results generalize to other populations.
In a prespecified interim analysis of the phase 3 TAISHAN-302 trial, tambotatug pelitecan significantly outperformed topotecan in relapsed small-cell lung cancer after platinum-based therapy, extending median overall survival (13.3 vs 9.4 months; hazard ratio 0.46) and progression-free survival (7.4 vs 2.8 months; hazard ratio 0.29), with a lower rate of grade ≥3 adverse events. Because overall survival data are not yet mature and the trial is open-label, and because the published abstract does not report subgroup or detailed per-arm safety data, these results should be read as a strong interim signal rather than a final, fully characterized comparison.